Skip to main content
Geneuro logo

Geneuro — Investor Relations & Filings

Ticker · GEM ISIN · CH0308403085 LEI · 213800FUJCKXO9LK3444 PA Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2018-12-20 Capital/Financing Update
Country CH Switzerland
Listing PA GEM

About Geneuro

https://geneuro.ch/en/

Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a new €7.5 million credit line agreement between GeNeuro and its shareholder, GNEH. It details the terms of the financing, the impact on liquidity, and the strategic implications for the company's development programs. This falls squarely under the definition of a capital or financing update, as it describes a specific fundraising/financing activity.
2018-12-20 English
Communicated under the obligation to provide permanent information / Other communications
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short press release (under 5,000 characters) announcing the results of a shareholder meeting. It explicitly states that the resolutions were approved and directs readers to the company website to view the detailed voting results. According to the 'Menu vs Meal' rule, this is an announcement of the results rather than the full voting report itself, making it a Declaration of Voting Results & Voting Rights Announcement (DVA).
2018-05-25 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release announcing the results of a shareholder vote at an Annual General Meeting (Assemblée Générale). It explicitly states that the shareholders approved all resolutions supported by the Board of Directors. Since it provides the official outcome of the voting process, it falls under the category of Declaration of Voting Results.
2018-05-25 French
Quarterly financial report / First quarter financial report
Earnings Release Classification · 1% confidence The document is a press release from GeNeuro titled 'financial information and business update for the first quarter 2018'. It provides key financial highlights (operating revenues, cash position) and business updates (clinical trial results, regulatory designations) for the first quarter. It is an initial announcement of quarterly results rather than a full comprehensive interim report, and it does not meet the criteria for a report publication announcement as it contains the actual financial data and business highlights within the text itself. Therefore, it is classified as an Earnings Release. Q1 2018
2018-05-09 English
Information financière trimestrielle / Information financière du premier trimestre
Earnings Release Classification · 1% confidence The document is a press release from GeNeuro titled 'information financière et point d'activité au 1er trimestre 2018'. It provides a summary of financial results (revenue, cash position) and operational updates (clinical trial progress) for the first quarter. It is not a full quarterly report (IR) but rather an initial announcement of these results, which fits the definition of an Earnings Release (ER). Q1 2018
2018-05-09 French
Communicated under the obligation to provide permanent information / Other communications
AGM Information Classification · 1% confidence The document is a letter from the Chairman and CEO of GeNeuro addressed to shareholders ahead of the upcoming Annual General Meeting (AGM) on May 24, 2018. It reviews company accomplishments and invites shareholders to participate in the meeting. Since it is a communication specifically prepared for the AGM context, it falls under the AGM-R category.
2018-05-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.